Serious potential via Creativ for the Cytodyn collaboration. All fingers crossed since 36+ news, for a Cytodyn shared equity stake, in Creativ Leronlimab assayings.
" Alzheimer's is also the most expensive disease in America. The cost of caring for people with Alzheimer's and other dementia was an
estimated $360 billion in 2024. Total costs are expected to exceed $1 trillion by 2050 unless we take meaningful action."
https://www.congress.gov/congressional-record...e/S8270-12
____
From Dec. 2025 Letter:
Our collaborator at Cornell has finalized a 12-week pilot study of leronlimab in patients with mild to moderate Alzheimer’s Disease. All the necessary approvals have been received, and the study is scheduled to begin screening after requisite equipment is installed at Cornell in April 2026."
___
LL returns phenomenal AZ data & LL makes it into Senate hearings, etc..
CCR5 route:
Game Changer
" Alzheimer's is also the most expensive disease in America. The cost of caring for people with Alzheimer's and other dementia was an
estimated $360 billion in 2024. Total costs are expected to exceed $1 trillion by 2050 unless we take meaningful action."
https://www.congress.gov/congressional-record...e/S8270-12
____
From Dec. 2025 Letter:
Our collaborator at Cornell has finalized a 12-week pilot study of leronlimab in patients with mild to moderate Alzheimer’s Disease. All the necessary approvals have been received, and the study is scheduled to begin screening after requisite equipment is installed at Cornell in April 2026."
___
LL returns phenomenal AZ data & LL makes it into Senate hearings, etc..
CCR5 route:
Game Changer
10
